⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CVKD News
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
globenewswire.com
CVKD
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
globenewswire.com
CVKD
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
globenewswire.com
CVKD
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
globenewswire.com
CVKD
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
globenewswire.com
CVKD
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
globenewswire.com
CVKD
Form 8-K
sec.gov
CVKD
Form 8-K
sec.gov
CVKD